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Objectives The study objectives were to test the hypotheses that ischemia during stress testing has prognostic value and
identifies those patients with coronary artery disease (CAD) with left ventricular (LV) dysfunction who derive the
greatest benefit from coronary artery bypass grafting (CABG) compared with medical therapy.
Background The clinical significance of stress-induced ischemia in patients with CAD and moderately to severely reduced
LV ejection fraction (EF) is largely unknown.
Methods The STICH (Surgical Treatment for IsChemic Heart Failure) trial randomized patients with CAD and EF 35% to
CABG or medical therapy. In the current study, we assessed the outcomes of those STICH patients who under-
went a radionuclide (RN) stress test or a dobutamine stress echocardiogram (DSE). A test was considered posi-
tive for ischemia by RN testing if the summed difference score (difference in tracer activity between stress and
rest) was 4 or if 2 of 16 segments were ischemic during DSE. Clinical endpoints were assessed by intention
to treat during a median follow-up of 56 months.
Results Of the 399 study patients (51 women, mean EF 26  8%), 197 were randomized to CABG and 202 were ran-
domized to medical therapy. Myocardial ischemia was induced during stress testing in 256 patients (64% of the
study population). Patients with and without ischemia were similar in age, multivessel CAD, previous myocardial
infarction, LV EF, LV volumes, and treatment allocation (all p  NS). There was no difference between patients
with and without ischemia in all-cause mortality (hazard ratio: 1.08; 95% confidence interval: 0.77 to 1.50; p 
0.66), cardiovascular mortality, or all-cause mortality plus cardiovascular hospitalization. There was no interac-
tion between ischemia and treatment for any clinical endpoint.
Conclusions In CAD with severe LV dysfunction, inducible myocardial ischemia does not identify patients with worse progno-
sis or those with greater benefit from CABG over optimal medical therapy. (Comparison of Surgical and Medical
Treatment for Congestive Heart Failure and Coronary Artery Disease [STICH]; NCT00023595) (J Am Coll
Cardiol 2013;61:1860–70) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.02.014Among patients with coronary artery disease (CAD), it is
widely accepted that the presence of myocardial ischemia
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2013, accepted February 3, 2013.induced during stress testing is associated with worse prognosis
and plays a role in the decision for myocardial revascularization
(1–3). The evidence substantiating such a critical significance
of stress-induced ischemia has emanated largely from studies in
patients with normal or only mildly impaired left ventricular
(LV) systolic function (4–6). In fact, until the recent
See page 1871
publication of the STICH (Surgical Treatment for
IsChemic Heart Failure) trial (7), none of the contemporary
studies addressing the impact of revascularization on out-
come of patients with CAD included those with moderately
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the clinical relevance of identifying the presence of inducible
ischemia in these patients is fundamentally unknown.
A growing number of patients with CAD present with
heart failure associated with LV systolic dysfunction as a
consequence of previous myocardial infarction(s) (11). In
these patients, improvement in LV function with revascu-
larization may be expected if there is a significant amount of
hypocontractile but viable myocardium. This concept has
been postulated on the basis of the results of retrospective
cohort studies and meta-analyses (12–15), but not proven in
prospective trials. Indeed, the recent viability substudy of
the STICH trial failed to show an interaction between
myocardial viability and the effect of coronary artery bypass
grafting (CABG) over optimal medical therapy on clinical
outcomes (16).
It is conceivable that the salutary effects of revasculariza-
tion are not mechanistically linked to the presence or extent
of viable myocardium, but rather to the overall extent of
jeopardized myocardium that might be identified by the
presence of inducible ischemia on stress testing. However,
there is no prospective randomized study to date demon-
strating the significance of ischemia in patients with CAD
and LV dysfunction. Thus, the present study was conducted
in the STICH trial population to test the hypotheses that
the presence of inducible myocardial ischemia identifies
those patients with CAD and LV dysfunction with worse
prognosis and those who derive the greatest benefit from
CABG compared with medical therapy.
Methods
Study population. STICH is a prospective, multicenter,
randomized trial sponsored by the National Heart, Lung,
and Blood Institute (NHLBI) that recruited 2,136 patients
with CAD and LV EF35% between 2002 and 2007. The
trial addressed two primary hypotheses: 1) CABG com-
bined with optimal medical therapy improves survival com-
pared with optimal medical therapy alone (surgical revascu-
larization hypothesis); and 2) surgical ventricular reconstruction
added to CABG improves survival free of cardiovascular
hospitalization compared with CABG alone in patients
with significant anterior wall akinesis (surgical ventricular
reconstruction hypothesis). The trial design and the results
of the two primary hypotheses have been reported (7,17,18).
Only the 1,212 patients in the surgical revascularization
hypothesis were considered for this study. The inclusion and
exclusion criteria and the requirements for ensuring high-
quality surgical revascularization have been described (17).
The NHLBI and the ethics committee at each recruiting
institution approved the study protocol. All patients pro-
vided written informed consent. A risk at randomization
(RAR) score was calculated for each patient with an
equation derived using multiple variables with known pre-
dictive power (19).Although noninvasive tests
were initially mandated as part of
the STICH trial protocol, this
requirement was discontinued to
facilitate patient enrollment.
Thus, only a proportion of pa-
tients included in STICH could
be considered for inclusion in
this study. Specifically, those pa-
tients who had a radionuclide
(RN) stress test or a dobutamine
stress echocardiogram (DSE)
within 90 days of randomization
and before the initiation of ther-
apy allocated by randomization
were selected.
Stress testing. For RN stress
testing, several protocols were al-
lowed, including exercise, dobut-
amine, and vasodilator stress
with adenosine or dipyridamole. Technetium-99m sesta-
mibi or tetrofosmin or thallium-201 was injected 1 minute
before the end of stress. Patients exercised to the develop-
ment of fatigue, chest pain, or ST-segment deviation, as is
customary in clinical practice. For adenosine stress, the
protocol used a 6-minute adenosine infusion (0.14 mg/kg/
min) with radiotracer injection 3 minutes into the infusion.
For dipyridamole stress, the tracer was injected 3 minutes
after the 4-minute infusion (0.14 mg/kg/min). For DSE,
conventional parasternal and apical images were obtained at
rest and during the infusion of incremental doses of dobut-
Comparison of Key Baseline Variables inSTICH Patients With nd Without Ischemia TestingTable 1 Comparison of Key Ba line Variables inSTICH Patients With and Without Ischemia Testing
Variable
Patients With
Ischemia Testing
(n  399)
Patients Without
Ischemia Testing
(n  813) p Value
Age (yrs) 61 10 60 9 0.07
Female 51 (13%) 97 (12%) 0.67
White race 331 (83%) 496 (61%) 0.0001
Body mass index (kg/m2) 27 4 27 5 0.31
History of myocardial
infarction
299 (75%) 635 (78%) 0.22
Previous CABG 11 (3%) 25 (3%) 0.76
Previous PCI 59 (15%) 97 (12%) 0.16
Advanced angina* 13 (3%) 45 (6%) 0.08
Advanced heart failure† 127 (32%) 320 (39%) 0.01
Multivessel disease‡ 289 (72%) 615 (76%) 0.21
LV EF (%) 26 8 29 8 0.0001
ESVI (ml/m2) 92 38 82 35 0.0001
EDVI (ml/m2) 123 41 114 38 0.001
ICD use§ 86 (22%) 117 (14%) 0.002
RAR score 13 9 13 9 0.66
Values are mean  SD or n (%). *Canadian Cardiac Society class III or IV. †New York Heart
Association functional class III or IV. ‡Presence of75% stenosis in 2 or 3 coronary arteries. §ICD
use at any point during the study.
CABG  coronary artery bypass grafting; EDVI  end-diastolic volume index; EF  ejection
Abbreviations
and Acronyms
CABG  coronary artery
bypass grafting
CAD  coronary artery
disease
DSE  dobutamine stress
echocardiogram
EF  ejection fraction
LV  left
ventricle/ventricular
NHLBI  National Heart,
Lung, and Blood Institute
RAR  risk at
randomization
RN  radionuclide
SDS  summed difference
scorefraction; ESVI  end-systolic volume index; ICD  intraca
PCI  percutaneous coronary intervention; RAR  risk atrdiac defibrillator; LV  left ventricular;
randomization.
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Ischemia and Outcome With LV Dysfunction May 7, 2013:1860–70amine. A DSE test was considered suitable to assess the
presence or absence of inducible ischemia (and thus in-
cluded in this study) if it met at least one of the following
criteria: 1) achievement of a dobutamine dose 30 g/kg/
in; 2) achievement of 85% of age-predicted maximum
eart rate; or 3) presence of myocardial ischemia (as defined
ater).
RN and DSE images were reviewed at core laboratories,
ndependently funded by the NHLBI, by investigators
linded to treatment assignment and all individual patient
haracteristics. Criteria for the presence or absence of
yocardial ischemia were defined prospectively and sepa-
ately for each method without knowledge of baseline
haracteristics, results of other tests, or follow-up outcomes.
For RN studies, a semiquantitative visual assessment of
yocardial perfusion was performed using a 17-segment
odel of the LV (20). In each segment, tracer activity was
ssessed using a 5-point scale, where 0  normal and 4 
bsent uptake of tracer. The scores for each of the 17
egments were summed to give the summed stress and
ummed rest scores. When dedicated viability imaging was
erformed along with the stress study, the “viability” images
ere used for the rest score. The summed difference score
SDS) was obtained by subtracting the stress from the rest
core and thus reflects the extent of the ischemic defect. An
N test was considered as positive for myocardial ischemia
Figure 1 Kaplan-Meier Estimates of the Primary and Secondary
Included and Excluded From This Substudy
The 813 STICH patients with no evaluable stress testing and excluded from this s
are shown on the right. A shows the results for the primary endpoint of all-causehen the SDS was 4. As a reflection of the overall tagnitude of ischemia, combining both ischemic extent and
everity of ischemia, the SDS also was analyzed as a
ontinuous variable expressed as the percent of the maxi-
um possible SDS (5,21,22).
For DSE analysis, the LV was divided into 16 segments
nd systolic wall thickening was assessed separately for each
egment (23). A segment was considered to display induc-
ble myocardial ischemia when systolic wall thickening
uring the infusion of dobutamine worsened when com-
ared with that seen at baseline or during the preceding
ose (24). A patient was considered to have a DSE positive
or ischemia when an ischemic response was observed in2
V segments (25). Myocardial ischemia also was analyzed
s a continuous variable expressed as the number (and
ercent) of ischemic segments.
In patients who had both RN and DSE tests, the
resence of an ischemic response on either test was consid-
red sufficient for the demonstration of ischemia.
ollow-up and outcomes. After enrollment, patients were
ollowed every 4 months for the first year and every 6
onths thereafter. The primary outcome was death from
ny cause. Secondary endpoints included death from car-
iovascular causes and a composite of death from any cause
r hospitalization for cardiovascular causes. Definitions of
he trial endpoints have been reported (7). All death causes
ere adjudicated by an independent clinical events commit-
points Among STICH Patients
re shown on the left. The 399 patients with stress testing included in this study
ity. Continued on the next pageEnd
tudy a
mortalee. Median follow-up was 56 months.
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May 7, 2013:1860–70 Ischemia and Outcome With LV DysfunctionStatistical analyses. Baseline patient characteristics are
descriptively summarized using mean  SD for continuous
variables and frequencies and percentages for categoric
variables. Because stress test information was not available
Figure 1 Continued
B and C show the results for the secondary endpoints of cardiovascular mortality
on intention to treat. CABG  coronary artery bypass grafting; MED  medical thefor every patient, we first examined the baseline character-istics and clinical outcomes of patients with a stress test
compared with the patients without a stress test. The distri-
butions of continuous or ordinal variables were compared
between groups using the Wilcoxon rank-sum test, and cate-
l-cause mortality or cardiovascular hospitalization, respectively. Analysis basedand al
rapy.goric variables were compared using the chi-square test or
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Ischemia and Outcome With LV Dysfunction May 7, 2013:1860–70Fisher exact test. The primary and secondary endpoints were
compared between patients in the stress-test cohort and the
patients without a stress test. Event-rate estimates in each
group and for each endpoint were calculated using the
Kaplan-Meier method (26) and statistically compared using
the log-rank test (27). Relative risks, expressed as hazard
ratios with associated 95% confidence intervals, were de-
rived using the Cox regression model (28). The log-rank
test and Cox model also were used to examine the random-
ized treatment comparisons with respect to the primary
and secondary endpoints among the patients in the
stress-test cohort and in the excluded patients to assess
comparability of treatment comparisons relative to the
overall trial results.
Analyses similar to those described earlier also were
performed to compare the baseline characteristics, the
primary and secondary endpoints, and the CABG versus
medical treatment comparisons in the patients with versus
those without myocardial ischemia during stress test (treat-
ing ischemia as a dichotomous variable). In addition, we
addressed the question of whether there was a differential
effect of CABG in patients with versus those without
demonstrated ischemia. This assessment was performed by
testing for the presence of a treatment by ischemia interac-
tion using the Cox model. Finally, ischemia was examined
as a continuous variable with the Cox model to assess the
relationship of the amount of ischemia with the primary and
secondary clinical endpoints.
The various treatment comparisons described earlier were
performed with the treatment groups defined according to
the randomized treatment assignments (intention to treat).
As previously reported (7), because of treatment crossovers,
some patients did not receive the treatment to which they
were randomized. Supplementary analyses were performed
on the basis of the treatment the patients actually received
(“as treated”), and excluding crossover patients (“per-
protocol”).
Results
Study population. A total of 399 patients (or 33% of those
enrolled in the STICH revascularization hypothesis trial)
fulfilled the inclusion criteria and were included in this
study. There were 348 men and 51 women. Mean age was
61 10 years, and mean EF was 26 8%. Of the 399 study
atients, 219 had an RN test and 205 had a DSE. Both tests
ere available for analysis in 25 patients. Table 1 shows a
omparison of key baseline characteristics between the 399
tudy patients and the 813 patients enrolled in STICH who
id not meet the inclusion criteria for this study. There was
greater proportion of white patients among those included
n this study because there was a higher rate of ischemia
ests performed in European countries where white race is
ore prevalent. The RAR score was similar in the 2 groups.
here were less advanced heart failure presentations and arend toward less advanced angina in the patients included tn this study. Of note, patients with ischemia testing had
ower LV EF and larger LV volumes, and a higher rate of
ntracardiac defibrillator use during the study. These find-
ngs notwithstanding, there were no statistically significant
ifferences between the patients included and those ex-
luded from this analysis in terms of all-cause mortality (p
.36) or cardiovascular mortality (p 0.32). Likewise, there
as no significant difference in the treatment effect of
ABG plus medical therapy versus medical therapy alone
mong the patients included in this study compared with
hose excluded because of the lack of ischemia data (Fig. 1).
nducible myocardial ischemia. Of the 399 study patients,
56 (64%) had demonstrable myocardial ischemia during
tress testing and 143 (36%) did not. Of note, the prevalence
f a positive ischemic response was similar among patients
ith an RN test (135 of 219, or 62%) and those with a DSE
est (129 of 205, or 63%). Table 2 shows a comparison of
ey characteristics between patients with and without myo-
ardial ischemia. None of the baseline characteristics were
ignificantly different between the two groups, although
here was a trend for a higher RAR score index in patients
ith ischemia.
When ischemia was analyzed as a continuous variable, the
ercent ischemic myocardium was 12.2 11.5% for the 399
atients included in the study and, as expected, was higher
mong those with an ischemic response (Table 2). The
mount of ischemic myocardium was 10% in 199 patients
or 50% of the study group) and 20% in 75 patients (or
9% of the study group).
ffect of ischemia on events during follow-up. When
yocardial ischemia was analyzed as a dichotomous vari-
ble, there was no difference in all-cause mortality between
atients with and without ischemia (Fig. 2). Likewise, there
ere no differences in outcomes between these 2 groups for the
econdary endpoints of cardiovascular mortality (Fig. 3A) or
eath plus cardiovascular hospitalization (Fig. 3B).
The impact of ischemia on clinical outcomes also was
nalyzed treating ischemia as a continuous variable. No
elationship was observed between the amount of ischemic
yocardium and the probability of an adverse outcome for
ll-cause mortality (p 0.28), cardiovascular mortality (p
.07), or death plus cardiovascular hospitalization (p 
.79). These findings were similar when the data were
nalyzed separately for patients with RN tests or DSE tests
data not shown).
nteraction between ischemia and treatment. Of the 399
atients included in the study, 197 were randomized to
ABG and 202 were randomized to medical therapy. The
umber of patients with an ischemic response was similar in
he 2 treatment groups: 129 of 197 (or 66%) in the CABG
roup and 127 of 202 (or 63%) in the medical therapy group
p  0.59).
In the intention-to-treat analysis, there was a trend
oward decreased all-cause mortality (p  0.13) and cardio-
ascular mortality (p  0.07), and a significant benefit in
erms of death or cardiovascular hospitalization (p  0.001)
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May 7, 2013:1860–70 Ischemia and Outcome With LV Dysfunctionfor CABG compared with medical therapy, similar to the
results observed for the entire population of 1,212 patients
included in the STICH trial surgical revascularization
hypothesis (7). However, no interaction was observed be-
tween the treatment effects of CABG over medical therapy
Comparison of Key Baseline VariablesBetween Patients With and Without InducibleMyoc rdial Ischemia on Stress Tes ing
Table 2
Comparis of Key Bas line Variables
Between Patients With and Without Inducible
Myocardial Ischemia on Stress Testing
Variable
Patients With
Ischemia
(n  256)
Patients Without
Ischemia
(n  143) p Value
Age (yrs) 61 10 60 9 0.27
Female 29 (11%) 22 (15%) 0.24
White race 212 (83%) 119 (83%) 0.95
Body mass index (kg/m2) 27 4 28 5 0.09
History of myocardial infarction 187 (73%) 112 (78%) 0.24
Previous CABG 9 (4%) 2 (1%) 0.34
Previous PCI 42 (16%) 17 (12%) 0.22
Advanced angina* 9 (4%) 4 (3%) 0.78
Advanced heart failure† 81 (32%) 46 (32%) 0.91
Multivessel disease‡ 192 (75%) 97 (68%) 0.12
LV EF (%) 26 8 26 8 0.38
ESVI (ml/m2) 91 37 94 39 0.55
EDVI (ml/m2) 121 41 125 41 0.31
ICD use§ 57 (22%) 29 (20%) 0.64
RAR score 14 9 12 9 0.07
Percent of ischemic myocardium 18 11 2 2 0.0001
Values are mean  SD or n (%). *Canadian Cardiac Society class III or IV. †New York Heart
ssociation functional class III or IV. ‡Presence of75% stenosis in 2 or 3 coronary arteries. §ICD
use at any point during the study.
Abbreviations as in Table 1.
Figure 2 Kaplan-Meier Estimates of All-Cause Mortality Rates
Study patients are divided according to the presence or absence of ischemia on sand the presence or absence of myocardial ischemia for
all-cause mortality (Fig. 4) or either of the secondary
endpoints (Fig. 5). When myocardial ischemia was assessed
as a continuous variable, there was no significant interaction
between the extent of ischemia and the treatment effect of
CABG on all-cause mortality (p  0.73) cardiovascular
ortality (p  0.79), or death plus cardiovascular hospital-
zation (p  0.89). Similar findings were observed when
atients were grouped according to treatment received (i.e.,
as treated” analysis) and when patients who crossed over
rom the randomized allocated treatment arm were excluded
i.e., “per protocol” analysis) (Table 3).
iscussion
espite the accepted significance of ischemia on stress
esting, the evidence supporting its role in the treatment
ecisions for patients with CAD with LV dysfunction is
nadequate, emanating from studies conducted in pa-
ients with normal or slightly reduced LV systolic func-
ion (4), from retrospective assessment of registries (21),
r from prospective trials with limited assessment of
schemia (5,8). Further, a major ongoing effort to determine
he best management strategy for patients with stable
AD and at least moderate ischemia—the ISCHEMIA
International Study of Comparative Health Effectiveness
ith Medical and Invasive Approaches) trial—will exclude
atients with EF 35% (NCT01471522).
resent study findings. The study results indicate that the
resence of inducible ischemia on stress testing in patients
esting, regardless of treatment allocation.tress t
1866 Panza et al. JACC Vol. 61, No. 18, 2013
Ischemia and Outcome With LV Dysfunction May 7, 2013:1860–70with CAD and severe LV dysfunction (mean EF: 26%) is
not associated with worse prognosis and does not identify
those with greater therapeutic benefit from surgical revas-
cularization. Thus, despite the trend for decreased overall
and cardiovascular mortality for CABG compared with
medical therapy, no interaction was found between the
treatment effect of surgical revascularization and the pres-
ence of ischemia. In essence, these results suggest that the
therapeutic effect of CABG is not limited to patients with
inducible myocardial ischemia on stress testing. Similar
findings were observed in separate analyses performed
Figure 3 Kaplan-Meier Rate Estimates of Secondary Endpoints
A shows the results for cardiovascular mortality and B shows the results for all-ca
Study patients are divided according to the presence or absence of ischemia on saccording to the treatment actually received (“as treated”analysis) and excluding patients not receiving the treatment
allocated by randomization (“per protocol” analysis).
Prior registry data have suggested a benefit of revasculariza-
tion only when moderate-to-severe ischemia was present (22).
However, in this study, the extent of myocardial ischemia was
not associated with worse prognosis or a beneficial effect of
CABG. The number of patients with moderate-severe isch-
emia was too small to provide a meaningful analysis of this
subset. Nonetheless, and in support of these findings, when
patients with extensive myocardial scarring were examined in
the prior registry, the presence of ischemia no longer identified
ng Patients With and Without Inducible Ischemia
ortality or cardiovascular hospitalization.
esting, regardless of treatment allocation.Amo
use m
tress tsurvival benefit from revascularization (22).
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May 7, 2013:1860–70 Ischemia and Outcome With LV DysfunctionStudy limitations. The performance of a stress test was not
mandated as part of the STICH trial protocol design and
was left to the discretion of the recruiting investigators. This
may have led to bias such that patients with severe ischemia
were less likely to be included in the trial, thus limiting the
number of patients in this cohort and reducing the statistical
power to determine a treatment by ischemia interaction.
Patients included in this study had more advanced forms of
the disease, as expressed, for example, by lower EF and
larger LV volumes. However, the outcomes of the 399
patients included in this study (regardless of treatment
allocation) were similar to those of the other 813 STICH
patients excluded from this analysis because of the lack of a
stress test. In addition, the treatment effect of CABG over
medical therapy was similar in the STICH patients included
in this study and those excluded. Moreover, the randomized
treatment assignment in the patients included in this study
was similar to that of the entire STICH population with
approximately half of the patients allocated to CABG.
Finally, among the study patients, treatment allocation also
was similar in patients with and without inducible ischemia.
This indicates that there were likely no clinically meaningful
biases to associate the performance of a stress test or its
Figure 4 Kaplan-Meier Rate Estimates of All-Cause Mortality R
Results for patients without ischemia are shown on the left and for patients with
CABG  coronary artery bypass grafting; MED medical therapy.results to the likelihood of randomization to surgical revas-cularization. Nevertheless, the power of the surgical revas-
cularization hypothesis was calculated for the entire STICH
trial population (7); therefore, no definitive conclusions
regarding the treatment effect of CABG in patients with
ischemic cardiomyopathy may be derived from the results of
this substudy.
We must also acknowledge that patients included in the
study did not have serial testing to ascertain that CABG (or
medical therapy) eliminated the presence of inducible is-
chemia. Thus, reduction of ischemia as a predictor of
outcomes could not be analyzed as part of this study.
Further, because we did not measure the presence or extent
of scar, we cannot determine the additive value of the
myocardial scarring information relative to that provided by
the presence of ischemia. Finally, although the concept of
complete revascularization was part of the STICH trial
protocol (18), we did not have the ability to ascertain that
the grafted coronary arteries corresponded to the location of
myocardial ischemia in each individual study patient.
Implications
A number of potential explanations may account for the
According to Treatment of Patients With or Without Ischemia
ia are shown on the right. Analysis based on intention to treat.ates
ischemfindings of this study and provide a framework for their
1868 Panza et al. JACC Vol. 61, No. 18, 2013
Ischemia and Outcome With LV Dysfunction May 7, 2013:1860–70Figure 5 Kaplan-Meier Rate Estimates of Secondary Endpoints According to Treatment of Patients With or Without Ischemia
A shows the results for cardiovascular mortality and B shows the results for all-cause mortality or cardiovascular hospitalization. Results for patients without ischemia are
shown on the left and for patients with ischemia are shown on the right. Analysis based on intention to treat. CABG  coronary artery bypass grafting; MED  medical therapy.
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May 7, 2013:1860–70 Ischemia and Outcome With LV Dysfunctioninterpretation. First, in the natural history process of coro-
nary atherosclerosis, once severe LV dysfunction and re-
modeling have developed, the occurrence of inducible isch-
emia may not play a major role and may therefore become
a less significant prognostic marker than in patients with
milder forms of the disease. Second, the benefit of surgical
revascularization may be related to the prevention of events
that are not mechanistically linked to the induction of
ischemia on stress testing. In this regard, a recent analysis on
the mode of death in the STICH trial showed that CABG
reduced the rate of sudden cardiac death and fatal myocar-
dial infarction (29). In conjunction with those observations,
the findings of this study suggest that the benefit of CABG
is related to the protection of jeopardized myocardium when
there is a subsequent arterial occlusion that might precipi-
tate lethal arrhythmias, which is not causally associated to the
lesion(s) responsible for ischemia during stress testing.
hird, medical therapy also may have reduced myocardial
schemia, thus limiting the therapeutic value of surgical
evascularization. Finally, the accuracy of imaging stress
esting may be diminished in patients with severe LV
ysfunction and remodeling, thus rendering the test less
seful for its intended purpose.
The findings of this study have important clinical impli-
ations. First, these observations do not argue against a
beneficial effect of CABG in patients with inducible ischemia.
Instead, they indicate that the presence of ischemia does not
select a group with greater benefit from revascularization.
On the basis of these results, the demonstration of myocar-
dial ischemia should not be viewed as a requisite for the
indication of surgical revascularization in these patients
(30). Thus, if CABG is indicated on the basis of the
patient’s clinical presentation, it should not be withheld
because ischemia is not demonstrated on noninvasive stud-
ies. Nevertheless, when making clinical decisions, the phy-
sician must integrate all available information, including the
location of ischemia, the possibility of imaging artifacts
affecting the accuracy of the test, and the feasibility of
regional revascularization, to formulate the best therapeutic
choice for each individual patient.
We have previously reported that the assessment of
myocardial viability in these patients does not identify those
with greater therapeutic benefit of CABG (16). It must be
noted that viability and inducible ischemia are distinct
concepts and phenomena—all myocardial segments show-
p Values for the Statistical Assessment ofInteraction Between Treatment and Presence orAbsen e of Ischemia for Each Pre-Determi edClinical E dpoint
Table 3
p Values for the Statistical Assessment of
Interaction Between Treatment and Presence or
Absence of Ischemia for Each Pre-Determined
Clinical Endpoint
Clinical Endpoint “As Treated” Analysis “Per Protocol” Analysis
All-cause mortality 0.28 0.41
Cardiovascular mortality 0.55 0.70
Death or cardiovascular
hospitalization
0.58 0.69ing inducible ischemia must be viable, but not all viablesegments are ischemic on stress testing. Further, not all
segments with inducible ischemia are dysfunctional at rest.
Thus, the findings of this study complement those previous
observations and provide the basis for a more thorough
understanding of the role of noninvasive imaging in the
evaluation of patients with CAD and severe LV dysfunction.
In this regard, the present study findings are in agreement with
previous retrospective reports showing that, even among pa-
tients in whom viability information was predictive of long-
term prognosis, the presence of inducible ischemia was not
associated with benefit from revascularization (31).
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